936 Results

People

  1. Tap
    Tap
  2. D'Angelo
    D'Angelo
  3. Gounder
    Gounder
  4. Chi
    Chi
  5. Dickson
    Dickson
  6. Antonescu
    Antonescu
  7. Keohan
    Keohan
  8. Singer
    Singer
  9. Kelly
    Kelly
  10. Qin
    Qin

Groups

  1. Department of Medicine (936)
  2. Sarcoma Service (936)
  3. Solid Tumor Oncology Division (936)
  4. GSK Faculty (336)
  5. Tow Center for Developmental Oncology (TCDO) (304)
  6. Hematologic Malignancies, Division of (289)
  7. Department of Pathology and Laboratory Medicine (237)
  8. Human Oncology and Pathogenesis Program (232)
  9. Surgery (199)
  10. Sarcoma Surgeons (142)
  1. "Sarcoma Service"
Formats
  1. Journal Article (444)
  2. Meeting Abstract (429)
  3. Review (26)
  4. Editorial (8)
  5. Guidelines (8)
  6. Book Section (6)
  7. Miscellaneous (6)
  8. Research Letter (6)
  9. Correspondence (2)
  10. Book Whole (1)
Groups
  1. Department of Medicine (936)
  2. Sarcoma Service (936)
  3. Solid Tumor Oncology Division (936)
  4. GSK Faculty (336)
  5. Tow Center for Developmental Oncology (TCDO) (304)
  6. Hematologic Malignancies, Division of (289)

More Groups

People
  1. William Tap (372)
  2. Sandra D'Angelo (252)
  3. Mrinal Gounder (228)
  4. Ping Chi (172)
  5. Mark Dickson (169)
  6. Cristina Antonescu (135)

More People

Years
  1. 2025 (27)
  2. 2024 (87)
  3. 2023 (79)
  4. 2022 (116)
  5. 2021 (76)
  6. 2020 (90)

More Years

Publications
  1. Journal of Clinical Oncology (272)
  2. Annals of Oncology (70)
  3. Clinical Cancer Research (60)
  4. Cancer Research (31)
  5. Journal for ImmunoTherapy of Cancer (25)
  6. Cancer (19)

More Publications

Publishers
  1. American Society of Clinical Oncology (286)
  2. American Association for Cancer Research (107)
  3. Oxford University Press (91)
  4. Elsevier Inc. (59)
  5. Nature Publishing Group (41)
  6. Springer (40)

More Publishers

Results (936)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies
    Journal Article

    Lopez, J. S.; Milhem, M.; Butler, M. O.; Thistlethwaite, F.; Van Tine, B. A.; D'Angelo, S. P.; Johnson, M. L.; Sato, T.; Arkenau, H. T.; Edukulla, R.; more...
    Cell Reports Medicine (2025)

    Fulltext@MSK | Save
  • Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies
    Review

    Reinhorn, D.; Moskovitz, M.; Tap, W. D.; Li, B. T.
    Cancer (2025)

    Fulltext@MSK | Save
  • Immunologic correlates in a CIC::DUX4 fusion-positive sarcoma responsive to dual immune checkpoint blockade
    Journal Article

    Babatunde, O. O.; Membribes, S. C.; Anthonescu, C.; Bradic, M.; O'Malley, B.; Linkov, I.; Bartlett, E.; Momtaz, P.; Alektiar, K.; Gounder, M. M.; more...
    npj Precision Oncology (2025)

    Fulltext@MSK | Save
  • Fifth subtype of Kaposi sarcoma in HIV-negative MSM: A retrospective single-arm cohort study from a tertiary care center in NYC from 2000 to 2022
    Journal Article

    Morales, A. E.; Benson, G.; Glavan, S.; Giuliano, R.; Dickson, M. A.
    The Oncologist (2025)

    Fulltext@MSK | Save
  • 3 things you should know about identifying and treating epithelioid sarcoma
    Miscellaneous

    Agulnik, M.; Gounder, M. M.; Kraveka, J. M.; Zuckerman, L. M.
    Oncology (Norwalk) (2025)

    Fulltext@MSK | Save
  • A phase I study of FHD-609, a heterobifunctional degrader of bromodomain-containing protein 9, in patients with advanced synovial sarcoma or SMARCB1-deficient tumors
    Journal Article

    Livingston, J. A.; Blay, J. Y.; Trent, J.; Valverde, C.; Agulnik, M.; Gounder, M.; Le Cesne, A.; McKean, M.; Wagner, M. J.; Stacchiotti, S.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Alternative driver pathways in peripheral nerve sheath tumors – Including DICER1 and/or KRAS alterations
    Journal Article

    Chang, H. Y.; Saoud, C.; Torrence, D.; Tap, W.; Chi, P.; Antonescu, C. R.
    Journal of Pathology (2025)

    Fulltext@MSK | Save
  • INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations
    Meeting Abstract

    Heinrich, M. C.; Blay, J. V.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Gelderblom, H.; Zalcberg, J. R.; Reichmann, W.; Sprott, K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Trent, J. C.; Wagner, A. J.; Attia, S.; Agulnik, M.; Wilky, B. A.; Tap, W. D.; von Mehren, M.; Davis, E. J.; Zou, L.; Shah, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • IDH1/2 mutations in cancer: Unifying insights and unlocking therapeutic potential for chondrosarcoma
    Review

    Deshmukh, S.; Kelly, C.; Tinoco, G.
    Targeted Oncology (2025)

    Fulltext@MSK | Save